VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SITC 2021 | Combining a DNA vaccine with pembrolizumab for mCRPC

Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, explains the rationale for combining a DNA vaccine with pembrolizumab to treat metastatic castration-resistant prostate cancer (mCRPC). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter